Alkermes plc. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Alkermes reported Q2 2026 revenues of $496.0M (vs. $390.7M in Q2 2025), with proprietary product sales of $411.7M. VIVITROL ($124.5M), ARISTADA ($96.7M), LYBALVI ($94.0M), and newly acquired LUMRYZ ($96.6M) drove growth. Blair Jackson assumes CEO role August 1, 2026, replacing Richard Pops who remains Chairman. Avadel acquisition (closed Feb 12, 2026) triggered a $26.4M increase in contingent consideration fair value following positive LUMRYZ phase 3 data. FY2026 guidance unchanged: total revenue $1.73B–$1.84B; GAAP net loss $95M–$115M; adjusted EBITDA $370M–$410M.
Why this rating
CEO transition is routine management succession. Avadel integration and LUMRYZ revenue (~$96.6M/quarter) represent real but manageable 2% of $4.7B market cap. CVR liability is non-cash and contained. Maintained guidance suggests stable execution.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.